Scholar Rock begins Phase 2 FORGE trial of apitegromab in facioscapulohumeral muscular dystrophy

• Scholar Rock received FDA Fast Track designation for apitegromab in facioscapulohumeral muscular dystrophy, adding to its Orphan Drug status.
• Participant dosing has started in the Phase 2 FORGE trial, positioning the program as a new clinical catalyst for the pipeline.
• Results have not been presented; the study is designed to read out whether apitegromab can increase lean muscle and support functional improvement.
• The program builds on prior late-stage evidence in spinal muscular atrophy showing motor-function improvement, supporting commercial upside if replicated in FSHD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202609020800BIZWIRE_USPR_____20260902_BW107955) on September 02, 2026, and is solely responsible for the information contained therein.